On Wednesday, Bank of America Corp (NYSE:BAC)’s shares inclined 1.49% to $17.33. With its recent share price change, BAC market value has reached roughly $177.85 billion. The company has a Profit Margin (ttm) of positive 30.40%. The operating profit margin is 74.10%. The stock’s performance in 1 month is -0.46% and its volatility for the same period is 2.12%.
Bank of America Corporation is a bank holding company. The company, through its auxiliaries, operates through Consumer and Business Banking; Consumer Real Estate Services; Global Wealth and Investment Administration; Global Banking; Global Markets; and Other segments.
Chevron Corporation (NYSE:CVX)’s shares gained 3.90% to $93.79.
Chevron Corporation (CVX) declared that its wholly-owned partner, Chevron U.S.A. Inc., has signed a non-binding liquefied natural gas (LNG) supply Heads of Agreement (HOA) with China Huadian Green Energy Co., Ltd. When the agreement is finalized, China Huadian Green Energy is predictable to receive up to 1 million metric tons per annum (MTPA) of LNG over 10 years starting in 2020.
“This is an important step in the commercialization of Chevron’s natural gas holdings in Australia and the establishment of our global liquefied natural gas portfolio,” said Pierre Breber, executive vice president, Chevron Gas and Midstream. “As Chevron continues to grow into one of the world’s largest LNG suppliers, this agreement represents further progress and diversification of our sales portfolio.”
“We welcome the opportunity to supply LNG to China Huadian and look forward to building lasting relationships with our customers in the region as the Chevron-operated Gorgon and Wheatstone projects move into operations,” said Roy Krzywosinski, managing director, Chevron Australia. “The China Huadia contract demonstrates Chevron’s equity gas from Australia is well-placed to meet the growing demand for natural gas in the Asia-Pacific region.”
China Huadian Green Energy Co. Ltd. is a partner of China Huadian Group, which is one of the largest state-owned power generation companies and has a leading role in gas-fired power generation in China.
Chevron Corporation, through its auxiliaries, engages in the petroleum, chemicals, and power and energy operations worldwide. The company operates in two segments, Upstream and Downstream.
Baxalta Inc (NYSE:BXLT)‘s shares dipped -1.13% to $39.32.
Baxalta Incorporated (BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, recently declared initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)]. ADYNOVATE was approved by the U.S. Food and Drug Administration (FDA) in November 2015 for use in adolescent and adult hemophilia patients (12 years and older) for on-demand treatment and control of bleeding, and prophylaxis to reduce the frequency of bleeding episodes.
The prospective, uncontrolled, open-label, multi-center Phase 3 study was designed to assess the safety and immunogenicity of ADYNOVATE. The study enrolled 73 formerly-treated patients (PTPs) with severe hemophilia A younger than 12 years of age and assessed the treatment’s hemostatic efficacy in prophylaxis and treatment of bleeding episodes. All participants received prophylactic ADYNOVATE treatment (median 1.9 infusions per week) and were followed for six months.
ADYNOVATE met its primary endpoint in the study, as no patients developed inhibitory antibodies to ADYNOVATE. In addition, no treatment-related serious adverse events were stated. More than 70 percent (72.7 percent) of patients had no joint bleeds while on treatment with ADYNOVATE and nearly 40 percent (37.9 percent) practiced zero bleeds. The median annualized bleeding rate (ABR) among patient participants treated with ADYNOVATE was 2.0 (range 0-49.8; mean ABR 3.0), which was comparable to the rates seen in the adult study.
“These initial efficacy and safety findings indicate a potentially valuable role for ADYNOVATE to treat pediatric patients with hemophilia A, with data compriseent with what was stated in clinical studies among adult patients,” said John Orloff, M.D., head of Research & Development and chief scientific officer, Baxalta. “We will continue to build evidence on the value of ADYNOVATE through our robust clinical development program, which will support additional global registrations in the coming years.”
Baxalta Incorporated, a biopharmaceutical company, develops, manufactures, and markets a portfolio of products primarily for the treatment of hematology and immunology worldwide. It also offers other therapies for the treatments of bleeding disorders, and chronic and acute medical conditions, counting hemophilia A, hemophilia B, attained hemophilia, inhibitor treatments, primary immunodeficiency (PID), and alpha-1 antitrypsin deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.